Health ❯ Medical Research ❯ Clinical Studies

Phase 3 Trials

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

FDA could issue a U.S. decision by March 28 under a faster review timeline, according to Reuters.

Viking Therapeutics Jumps After Wider Q3 Loss as R&D Ramp Signals Obesity-Drug Progress